Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma

Leukemia

Volumn 28, Issue 2, 2014, Pages 398-403

  Greenberg, A J ^a,b   Rajkumar, S V ^a   Therneau, T M ^b   Singh, P P ^a   Dispenzieri, A ^a   Kumar, S K ^a  

^a MAYO CLINIC   (United States)

^b Department of Health Sciences Research ^*  (United States)

Author keywords

bone lesions; cytogenetic abnormalities; mutliple myeloma; myeloma defining event; renal failure; translocations

Indexed keywords

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MULTIPLE MYELOMA; PROGNOSIS;

EID: 84893790538     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.258     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095-1110.
3. Kyle R, Rajkumar S. Criteria for diagnosis, staging, risk stratification, and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
4. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Guiterrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
5. Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia 2010; 24: 623-628.
6. Rajkumar S. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
7. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489-3495.
8. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802-809.
9. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
10. Gertz M, Lacy M, Dispenzieri A, Greipp P, Litzow M, Henderson K et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
11. Kapoor P, Fonseca R, Rajkumar S, Sinha S, Gertz M, Stewart A et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc 2010; 85: 532-537.
12. Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056-4061.
13. Perez-Simon J, Garcia-0Sanz R, Tabernero M, Almeida J, Gonzalez M, Fernandez-Calco J et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: aFISH analysis of 15 different chromosomes. Blood 1998; 91: 3366-3371.
14. Shaughnessy JJ, Haessler J, Fv Rhee, Anaissie E, Pineda-Roman M, Cottler-Fox M et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol 2007; 173: 530-536.
15. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100-2105.
16. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27: 1738-1744.
17. Chng W, Wier SV, Ahmann G, Winkler J, Jalal S, Bergsagel P et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005; 106: 2156-2161.
18. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013; 27: 711-717.
19. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 78-88.
20. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
21. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
22. Talamo G, Faroog U, Zangari M, Liao J, Dolloff NG, Loughran TPJ et al. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk 2010; 10: 464-468.